{"entity":{"type":"insider","cik":"0001790214","url":"/insider/0001790214","json_url":"/insider/0001790214.json","name":"Zuga Matt","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":19,"n_filings":12,"first":"2019-11-13","last":"2026-01-23","span_basis":"filed_date"},"name_variants":[{"name":"Zuga Matt","source":"filing","n_filings":12,"first_seen":"2019-11-13","last_seen":"2026-01-23"}],"transactions":[{"id":6076952,"accession":"0001628280-26-003347","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001628280-26-003347","line_url":"/filing/0001628280-26-003347#line-2","is_derivative":false,"issuer_cik":"0001576885","issuer_name":"Acumen Pharmaceuticals, Inc.","issuer_ticker":"ABOS","issuer_name_source":null,"issuer_url":"/issuer/0001576885","owner_cik":"0001790214","owner_name":"Zuga Matt","owner_display_name":"Zuga Matt","owner_url":"/insider/0001790214","role":"Officer (CFO & Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (CFO & Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO & Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1687.0,"shares_display":"1,687","price_per_share":1.86,"price_display":"1.86","price_state":"stated","total_value":3137.82,"total_display":"3,137.82","total_whole":"3,138","shares_owned_after":304924.0,"shares_owned_after_display":"304,924","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-22","filed_date":"2026-01-23","scope":"insider"},{"id":6076950,"accession":"0001628280-26-003347","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-26-003347","line_url":"/filing/0001628280-26-003347#line-1","is_derivative":false,"issuer_cik":"0001576885","issuer_name":"Acumen Pharmaceuticals, Inc.","issuer_ticker":"ABOS","issuer_name_source":null,"issuer_url":"/issuer/0001576885","owner_cik":"0001790214","owner_name":"Zuga Matt","owner_display_name":"Zuga Matt","owner_url":"/insider/0001790214","role":"Officer (CFO & Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (CFO & Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO & Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2473.0,"shares_display":"2,473","price_per_share":1.8072,"price_display":"1.81","price_state":"stated","total_value":4469.2056,"total_display":"4,469.21","total_whole":"4,469","shares_owned_after":306611.0,"shares_owned_after_display":"306,611","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-21","filed_date":"2026-01-23","scope":"insider"},{"id":6149711,"accession":"0001628280-26-001898","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-26-001898","line_url":"/filing/0001628280-26-001898#line-1","is_derivative":false,"issuer_cik":"0001576885","issuer_name":"Acumen Pharmaceuticals, Inc.","issuer_ticker":"ABOS","issuer_name_source":null,"issuer_url":"/issuer/0001576885","owner_cik":"0001790214","owner_name":"Zuga Matt","owner_display_name":"Zuga Matt","owner_url":"/insider/0001790214","role":"Officer (CFO & Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (CFO & Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO & Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6888.0,"shares_display":"6,888","price_per_share":1.8166,"price_display":"1.82","price_state":"stated","total_value":12512.7408,"total_display":"12,512.74","total_whole":"12,513","shares_owned_after":209951.0,"shares_owned_after_display":"209,951","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-08","filed_date":"2026-01-12","scope":"insider"},{"id":5835258,"accession":"0001628280-26-001265","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001628280-26-001265","line_url":"/filing/0001628280-26-001265","is_derivative":false,"issuer_cik":"0001576885","issuer_name":"Acumen Pharmaceuticals, Inc.","issuer_ticker":"ABOS","issuer_name_source":null,"issuer_url":"/issuer/0001576885","owner_cik":"0001790214","owner_name":"Zuga Matt","owner_display_name":"Zuga Matt","owner_url":"/insider/0001790214","role":"Officer (CFO & Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (CFO & Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO & Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5805.0,"shares_display":"5,805","price_per_share":1.9924229112833765,"price_display":"1.99","price_state":"stated","total_value":11566.015,"total_display":"11,566.02","total_whole":"11,566","shares_owned_after":218539.0,"shares_owned_after_display":"218,539","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-07","filed_date":"2026-01-07","scope":"insider","n_lines":2},{"id":5835252,"accession":"0001628280-26-001265","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001628280-26-001265","line_url":"/filing/0001628280-26-001265#line-2","is_derivative":false,"issuer_cik":"0001576885","issuer_name":"Acumen Pharmaceuticals, Inc.","issuer_ticker":"ABOS","issuer_name_source":null,"issuer_url":"/issuer/0001576885","owner_cik":"0001790214","owner_name":"Zuga Matt","owner_display_name":"Zuga Matt","owner_url":"/insider/0001790214","role":"Officer (CFO & Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (CFO & Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO & Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5100.0,"shares_display":"5,100","price_per_share":1.9662,"price_display":"1.97","price_state":"stated","total_value":10027.62,"total_display":"10,027.62","total_whole":"10,028","shares_owned_after":222644.0,"shares_owned_after_display":"222,644","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-06","filed_date":"2026-01-07","scope":"insider"},{"id":5835250,"accession":"0001628280-26-001265","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-26-001265","line_url":"/filing/0001628280-26-001265#line-1","is_derivative":false,"issuer_cik":"0001576885","issuer_name":"Acumen Pharmaceuticals, Inc.","issuer_ticker":"ABOS","issuer_name_source":null,"issuer_url":"/issuer/0001576885","owner_cik":"0001790214","owner_name":"Zuga Matt","owner_display_name":"Zuga Matt","owner_url":"/insider/0001790214","role":"Officer (CFO & Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (CFO & Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO & Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":1.9606,"price_display":"1.96","price_state":"stated","total_value":7842.4,"total_display":"7,842.40","total_whole":"7,842","shares_owned_after":227744.0,"shares_owned_after_display":"227,744","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-05","filed_date":"2026-01-07","scope":"insider"},{"id":4052043,"accession":"0001104659-25-023484","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-023484","line_url":"/filing/0001104659-25-023484#line-1","is_derivative":false,"issuer_cik":"0001184421","issuer_name":"ELUTIA INC.","issuer_ticker":"ELUT","issuer_name_source":null,"issuer_url":"/issuer/0001184421","owner_cik":null,"owner_name":"HighCape Partners GP, LLC; RAKIN KEVIN; HIGHCAPE PARTNERS QP, L.P.; HighCape Partners GP II, L.P.; HighCape Capital, LLC; Zuga Matt; HIGHCAPE PARTNERS, L.P.; HighCape Capital, L.P.; HighCape Partners GP, L.P.; HighCape Co-Investment Vehicle I, LLC","owner_display_name":"HighCape Partners GP, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":420000.0,"shares_display":"420,000","price_per_share":2.5,"price_display":"2.50","price_state":"stated","total_value":1050000.0,"total_display":"1,050,000.00","total_whole":"1,050,000","shares_owned_after":9520232.0,"shares_owned_after_display":"9,520,232","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-02-03","filed_date":"2025-03-13","scope":"insider"},{"id":4722906,"accession":"0001576885-25-000037","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001576885-25-000037","line_url":"/filing/0001576885-25-000037#line-2","is_derivative":false,"issuer_cik":"0001576885","issuer_name":"Acumen Pharmaceuticals, Inc.","issuer_ticker":"ABOS","issuer_name_source":null,"issuer_url":"/issuer/0001576885","owner_cik":"0001790214","owner_name":"Zuga Matt","owner_display_name":"Zuga Matt","owner_url":"/insider/0001790214","role":"Officer (CFO & Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (CFO & Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO & Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":28902.0,"shares_display":"28,902","price_per_share":1.7173,"price_display":"1.72","price_state":"stated","total_value":49633.4046,"total_display":"49,633.40","total_whole":"49,633","shares_owned_after":231744.0,"shares_owned_after_display":"231,744","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-23","filed_date":"2025-01-23","scope":"insider"},{"id":4722901,"accession":"0001576885-25-000037","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001576885-25-000037","line_url":"/filing/0001576885-25-000037#line-1","is_derivative":false,"issuer_cik":"0001576885","issuer_name":"Acumen Pharmaceuticals, Inc.","issuer_ticker":"ABOS","issuer_name_source":null,"issuer_url":"/issuer/0001576885","owner_cik":"0001790214","owner_name":"Zuga Matt","owner_display_name":"Zuga Matt","owner_url":"/insider/0001790214","role":"Officer (CFO & Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (CFO & Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO & Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4364.0,"shares_display":"4,364","price_per_share":1.6009,"price_display":"1.60","price_state":"stated","total_value":6986.3276,"total_display":"6,986.33","total_whole":"6,986","shares_owned_after":260646.0,"shares_owned_after_display":"260,646","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-21","filed_date":"2025-01-23","scope":"insider"},{"id":4822580,"accession":"0001576885-25-000011","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001576885-25-000011","line_url":"/filing/0001576885-25-000011#line-1","is_derivative":false,"issuer_cik":"0001576885","issuer_name":"Acumen Pharmaceuticals, Inc.","issuer_ticker":"ABOS","issuer_name_source":null,"issuer_url":"/issuer/0001576885","owner_cik":"0001790214","owner_name":"Zuga Matt","owner_display_name":"Zuga Matt","owner_url":"/insider/0001790214","role":"Officer (CFO & Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (CFO & Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO & Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13235.0,"shares_display":"13,235","price_per_share":1.8411,"price_display":"1.84","price_state":"stated","total_value":24366.9585,"total_display":"24,366.96","total_whole":"24,367","shares_owned_after":198210.0,"shares_owned_after_display":"198,210","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-03","filed_date":"2025-01-07","scope":"insider"},{"id":3210256,"accession":"0001576885-24-000026","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001576885-24-000026","line_url":"/filing/0001576885-24-000026#line-1","is_derivative":false,"issuer_cik":"0001576885","issuer_name":"Acumen Pharmaceuticals, Inc.","issuer_ticker":"ABOS","issuer_name_source":null,"issuer_url":"/issuer/0001576885","owner_cik":"0001790214","owner_name":"Zuga Matt","owner_display_name":"Zuga Matt","owner_url":"/insider/0001790214","role":"Officer (CFO & Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (CFO & Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO & Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4242.0,"shares_display":"4,242","price_per_share":3.705,"price_display":"3.70","price_state":"stated","total_value":15716.61,"total_display":"15,716.61","total_whole":"15,717","shares_owned_after":211445.0,"shares_owned_after_display":"211,445","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-18","filed_date":"2024-01-19","scope":"insider"},{"id":6928169,"accession":"0001104659-22-125197","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-22-125197","line_url":"/filing/0001104659-22-125197#line-1","is_derivative":false,"issuer_cik":"0001184421","issuer_name":"AZIYO BIOLOGICS, INC.","issuer_ticker":"AZYO","issuer_name_source":null,"issuer_url":"/issuer/0001184421","owner_cik":null,"owner_name":"HighCape Co-Investment Vehicle I, LLC; HIGHCAPE PARTNERS, L.P.; HighCape Partners GP, L.P.; RAKIN KEVIN; Zuga Matt; HighCape Capital, LLC; HighCape Capital, L.P.; HIGHCAPE PARTNERS QP, L.P.; HighCape Partners GP, LLC; HighCape Co-Investment Vehicle II, LLC","owner_display_name":"HighCape Co-Investment Vehicle I, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":735000.0,"shares_display":"735,000","price_per_share":4.75,"price_display":"4.75","price_state":"stated","total_value":3491250.0,"total_display":"3,491,250.00","total_whole":"3,491,250","shares_owned_after":5597604.0,"shares_owned_after_display":"5,597,604","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-12-05","filed_date":"2022-12-07","scope":"insider"},{"id":5460287,"accession":"0001104659-21-148591","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-21-148591","line_url":"/filing/0001104659-21-148591","is_derivative":false,"issuer_cik":"0001184421","issuer_name":"AZIYO BIOLOGICS, INC.","issuer_ticker":"AZYO","issuer_name_source":null,"issuer_url":"/issuer/0001184421","owner_cik":null,"owner_name":"HighCape Capital, L.P.; HighCape Capital, LLC; HighCape Co-Investment Vehicle I, LLC; HighCape Partners GP, LLC; HIGHCAPE PARTNERS QP, L.P.; HighCape Co-Investment Vehicle II, LLC; HIGHCAPE PARTNERS, L.P.; Zuga Matt; RAKIN KEVIN; HighCape Partners GP, L.P.","owner_display_name":"HighCape Capital, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":412735.0,"shares_display":"412,735","price_per_share":4.24,"price_display":"4.24","price_state":"stated","total_value":1749996.4,"total_display":"1,749,996.40","total_whole":"1,749,996","shares_owned_after":4862604.0,"shares_owned_after_display":"4,862,604","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-12-08","filed_date":"2021-12-10","scope":"insider","n_lines":2},{"id":8346236,"accession":"0001826279-23-000002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001826279-23-000002","line_url":"/filing/0001826279-23-000002#line-1","is_derivative":false,"issuer_cik":"0001184421","issuer_name":"ELUTIA INC.","issuer_ticker":"ELUT","issuer_name_source":null,"issuer_url":"/issuer/0001184421","owner_cik":null,"owner_name":"HighCape Partners GP, L.P.; HIGHCAPE PARTNERS QP, L.P.; HighCape Partners QP II, L.P.; HIGHCAPE PARTNERS, L.P.; RAKIN KEVIN; Zuga Matt; HighCape Partners GP II, L.P.; HighCape Partners GP, LLC; HighCape Partners GP II, LLC; HighCape Capital, L.P.","owner_display_name":"HighCape Partners GP, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2837128.0,"shares_display":"2,837,128","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":8434732.0,"shares_owned_after_display":"8,434,732","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-21","filed_date":"2023-10-05","scope":"insider"},{"id":3288001,"accession":"0001104659-20-114637","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-20-114637","line_url":"/filing/0001104659-20-114637#line-3","is_derivative":false,"issuer_cik":"0001184421","issuer_name":"AZIYO BIOLOGICS, INC.","issuer_ticker":"AZYO","issuer_name_source":null,"issuer_url":"/issuer/0001184421","owner_cik":null,"owner_name":"HighCape Capital, LLC; HighCape Co-Investment Vehicle I, LLC; HighCape Partners GP, LLC; HIGHCAPE PARTNERS QP, L.P.; HighCape Co-Investment Vehicle II, LLC; HighCape Capital, L.P.; HIGHCAPE PARTNERS, L.P.; RAKIN KEVIN; HighCape Partners GP, L.P.; Zuga Matt","owner_display_name":"HighCape Capital, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":441176.0,"shares_display":"441,176","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":7499992.0,"total_display":"7,499,992.00","total_whole":"7,499,992","shares_owned_after":4508831.0,"shares_owned_after_display":"4,508,831","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-10-13","filed_date":"2020-10-13","scope":"insider"},{"id":8022681,"accession":"0001192482-19-000428","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001192482-19-000428","line_url":"/filing/0001192482-19-000428","is_derivative":false,"issuer_cik":"0001561921","issuer_name":"TELA Bio, Inc.","issuer_ticker":"TELA","issuer_name_source":null,"issuer_url":"/issuer/0001561921","owner_cik":"0001790214","owner_name":"Zuga Matt","owner_display_name":"Zuga Matt","owner_url":"/insider/0001790214","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":86121.0,"shares_display":"86,121","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":1119573.0,"total_display":"1,119,573.00","total_whole":"1,119,573","shares_owned_after":260808.0,"shares_owned_after_display":"260,808","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-11-08","filed_date":"2019-11-13","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":13,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":2,"open_market":true},{"code":"S","label":"Open-market sale","n":11,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":13},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001576885","name":"Acumen Pharmaceuticals, Inc.","url":"/issuer/0001576885","role":"Officer (CFO & Chief Business Officer)","n_filings":6,"first_seen":"2024-01-19","last_seen":"2026-01-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001708527","name":"ELUTIA INC.","url":"/issuer/0001708527","role":"Director, Ten percent owner","n_filings":5,"first_seen":"2020-10-13","last_seen":"2025-03-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001561921","name":"TELA Bio, Inc.","url":"/issuer/0001561921","role":"Director","n_filings":1,"first_seen":"2019-11-13","last_seen":"2019-11-13"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001790214","retrieved_at":"2026-08-25T18:39:44+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}